Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | KIF11 | P52732 | 5/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8248041 | 1.00 | HTT (1.00) | HTTTHRBKIF11CTSVCTSL | |
| SCHEMBL8898607 | 1.00 | HTT (1.00) | HTTTHRBKIF11CTSVCTSL | |
| SCHEMBL8898611 | 1.00 | HTT (1.00) | HTTTHRBKIF11CTSVCTSL | |
| SCHEMBL8898736 | 0.99 | HTT (0.98) | HTTTHRBKIF11CTSVCTSL | |
| Hydrochloric Acid SCHEMBL31741907 | 0.99 | HTT (0.98) | HTTTHRBKIF11CTSVCTSL | |
| Hydrochloric Acid SCHEMBL1271897 | 0.99 | HTT (0.98) | HTTTHRBKIF11CTSVCTSL | |
| Hydrochloric Acid SCHEMBL1271899 | 0.99 | HTT (0.98) | HTTTHRBKIF11CTSVCTSL | |
| Hydrochloric Acid SCHEMBL1061360 | 0.99 | HTT (0.98) | HTTTHRBKIF11CTSVCTSL | |
| SCHEMBL8898703 | 0.87 | THRB (0.77) | HTTTHRBKIF11CTSVCTSL | |
| SCHEMBL8900565 | 0.87 | THRB (0.77) | HTTTHRBKIF11CTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124215-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | THE FRANCIS CRICK INST LIMITED (GB) | 2026-05-07 | — | — | US | claimed |
| US-20250333792-A1 | GENE PANEL FOR IDENTIFYING HYPO SEPSIS PHENOTYPE PATIENTS | UNIV FLORIDA (US) | 2025-10-30 | — | — | US | claimed |
| EP-4598518-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | The Francis Crick Institute Limited (GB) | 2025-08-13 | — | — | EP | claimed |
| WO-2024074554-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2024-04-11 | — | — | WO | claimed |
| US-11560596-B2 | Method for expecting and diagnosing UQCRB-related disease | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2023-01-24 | — | — | US | claimed |
| US-20260124215-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | THE FRANCIS CRICK INST LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-4659812-A1 | DETECTION METHODS AND COMBINATION THERAPIES OF CELLS WITH EXTRACELLULAR RAS EXPRESSION | Bumm, Thomas (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250333792-A1 | GENE PANEL FOR IDENTIFYING HYPO SEPSIS PHENOTYPE PATIENTS | UNIV FLORIDA (US) | 2025-10-30 | — | — | US | disclosed |
| US-12427155-B2 | Treatment for tau-related diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-30 | — | — | US | disclosed |
| US-12403104-B2 | Compounds and methods of promoting myelination | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4598518-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | The Francis Crick Institute Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-11560596-B2 | Method for expecting and diagnosing UQCRB-related disease | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2023-01-24 | — | — | US | disclosed |
| US-20230000798-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | CASE WESTERN RESERVE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| WO-2022271547-A1 | COMBINATION TREATMENT OF CANCER WITH A PARP INHIBITOR AND A LIPOPHILIC STATIN | TESARO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220324798-A1 | FERROPTOSIS INDUCING COMPOUND, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF INDUCING FERROPTOSIS | UNIVERSITY OF MASSACHUSETTS | 2022-10-13 | — | — | US | disclosed |
| WO-2022208169-A1 | PULSATILE PROTOCOLS FOR CANCER TREATMENT METHODS AND USES | CLINICS OPERATIONS LIMITED (GB) | 2022-10-06 | — | — | WO | disclosed |
| CN-114652735-A | Compounds and methods for promoting myelination | 凯斯西储大学 | 2022-06-24 | — | — | CN | disclosed |
| US-11344511-B2 | Compounds and methods of promoting myelination | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-05-31 | — | — | US | disclosed |
| EP-2247558-B1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2022-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12403104-B2 | Compounds and methods of promoting myelination | GMFG, MAG, SGMS1 | HTT 3587/4885THRB 2253/4885KIF11 1168/4885 |
| US-11344511-B2 | Compounds and methods of promoting myelination | GMFG, MAG, SGMS1 | HTT 3587/4885THRB 2253/4885KIF11 1168/4885 |
| US-20260124215-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | FDFT1, FNTA, FNTB | HTT 3414/4885THRB 2495/4885KIF11 3418/4885 |
| US-12427155-B2 | Treatment for tau-related diseases | MAPT, PSEN1, PSEN2 | HTT 22/4885THRB 2078/4885KIF11 449/4885 |
| US-20230000798-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | GMFG, MAG, SGMS1 | HTT 3587/4885THRB 2253/4885KIF11 1168/4885 |
| US-20220324798-A1 | FERROPTOSIS INDUCING COMPOUND, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF INDUCING FERROPTOSIS | AIFM2, AIFM1, FECH | HTT 3306/4885THRB 2072/4885KIF11 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.